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ABSTRACT
Objectives To provide information on the frequency and
reasons for outcome reporting bias in clinical trials.
Design Trial protocols were compared with subsequent
publication(s) to identify any discrepancies in the
outcomes reported, and telephone interviews were
conductedwiththerespectivetrialiststoinvestigatemore
extensively the reporting of the research and the issue of
unreported outcomes.
Participants Chief investigators, or lead or coauthors of
trials, were identified from two sources: trials published
since 2002 covered in Cochrane systematic reviews
where at least one trial analysed was suspected of being
at risk of outcome reporting bias (issue 4, 2006; issue 1,
2007, and issue 2, 2007 of the Cochrane library); and a
random sample of trial reports indexed on PubMed
between August 2007 and July 2008.
Setting Australia, Canada, Germany, the Netherlands,
NewZealand,theUnitedKingdom,andtheUnitedStates.
Main outcome measures Frequency of incomplete
outcome reporting—signified by outcomes that were
specified in a trial’s protocol but not fully reported in
subsequent publications—and trialists’ reasons for
incomplete reporting of outcomes.
Results 268 trials were identified for inclusion (183 from
the cohort of Cochrane systematic reviews and 85 from
PubMed). Initially, 161 respective investigators
responded to our requests for interview, 130 (81%) of
whom agreed to be interviewed. However, failure to
achieve subsequent contact, obtain a copy of the study
protocol, or both meant that final interviews were
conducted with 59 (37%) of the 161 trialists. Sixteen trial
investigators failed to report analysed outcomes at the
time of the primary publication, 17 trialists collected
outcome data that were subsequently not analysed, and
fivetrialistsdidnot measurea prespecifiedoutcomeover
the course of the trial. In almost all trials in which
prespecified outcomes had been analysed but not
reported (15/16, 94%), this under-reporting resulted in
bias. In nearly a quarter of trials in which prespecified
outcomes had been measured but not analysed (4/17,
24%), the “direction” of the main findings influenced the
investigators’ decision not to analyse the remaining data
collected. In 14 (67%) of the 21 randomly selected
PubMed trials, there was at least one unreported efficacy
or harm outcome. More than a quarter (6/21, 29%) of
these trials were found to have displayed outcome
reporting bias.
Conclusion The prevalence of incomplete outcome
reporting is high. Trialists seemed generally unaware of
the implications for the evidence base of not reporting all
outcomes and protocol changes. A general lack of
consensus regarding the choice of outcomes in particular
clinical settings was evident and affects trial design,
conduct, analysis, and reporting.
INTRODUCTION
Publication of complete trial results is important to
allow clinicians, consumers, and policy makers to
make better informed decisions about healthcare.
Not reporting a study on the basis of the strength and
“direction” of the trial results has been termed “publi-
cation bias.”
1 An additional and potentially more ser-
iousthreattothevalidityofevidencebasedmedicineis
the selection for publication of a subset of the original
recordedoutcomesonthebasisoftheresults,
2whichis
referred to as “outcome reporting bias.” The results
that the reader sees in the publication may appear to
be unselected, but a larger data set from which those
results may have been selected could be hidden. This
kind of bias affects not just the interpretation of the
individual trial but also any subsequent systematic
review of the evidence base that includes it.
3
The recent scientific literature has given some atten-
tion to the problems associated with incomplete out-
come reporting, and there is little doubt that non-
reporting of prespecified outcomes has the potential
to cause bias.
4-6 Eight previous studies have described
discrepancies with respect to outcomes between the
protocol or trial registry entry of randomised trials
and subsequent publications.
47-14 In two of these
studies,
48 trialists were surveyed to ascertain the fre-
quency and reasons for under-reporting outcomes.
Although both studies had relatively low response
rates, results showed that lack of clinical importance
(7/23; 18/29), lack of statistical significance (7/23;
13/29), and journal space restrictions (7/23) were the
reasons most often cited for under-reporting.
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and follow-up survey of trial investigators confirmed
these reasons for non-reporting.
15 However, informa-
tion from self reported questionnaires suggested trial-
ists often did not acknowledge the existence of
unreported outcomes, even when there was evidence
to the contrary in their publication.
Weundertookastudycomparingtheoutcomesspe-
cifiedintrialprotocolswiththoseinpublishedreports,
and obtained detailed information relating to discre-
pancies from trial investigators by means of a struc-
tured telephone interview. Our objectives were to
explore all discrepancies between outcomes specified
in the protocol and those reported in the trial publica-
tion, identify cases of selective reporting of the set of
outcomes measured, assess whether outcome report-
ing bias had occurred, and provide a more detailed
understandingofwhytrialistsdonotreportpreviously
specified outcomes.
METHODS
We compared trial protocols with subsequent reports,
and then conducted interviews by telephone with the
trialists to obtain information relating to discrepancies.
AllinterviewswereconductedinEnglish;becausesome
of the investigators were overseas, we ascertained the
feasibility of doing this with the researcher beforehand.
The project was not required to be reviewed under the
terms of the governance arrangements for research
ethics committees in the United Kingdom. However,
trialists were informed that confidentiality would be
assured and all identifiable data from the interviews
would be shared only by immediate members of the
research team (AJ, JJK, PRW, and RMDS).
Participants
ThestudyreportedherewaspartofthelargerOutcome
ReportingBiasinTrials(ORBIT)projecttoestimatethe
prevalence and effect ofoutcome reporting bias in clin-
ical trials on the primary outcomes of systematic
reviews from three issues of the Cochrane Library:
issue4,2006;issue1,2007,andissue2,2007.
3Toassess
theriskofoutcomereportingbiasinthiscontext,aclas-
sification system was developed and applied when a
trial was excluded from a meta-analysis either because
dataforthe reviewprimaryoutcome were not reported
or because data were reported incompletely (for exam-
ple, just as “not significant”). The system identified
whether there was evidence that: (a) the outcome was
measured and analysed but only partially reported; (b)
the outcome was measured but not necessarily ana-
lysed; (c) it was unclear whether the outcome was mea-
sured; or (d) it was clear that the outcome was not
measured. One project researcher and the correspond-
ing author of the review independently classified any
trial in the review that did not report or partially
reported results for the review primary outcome on
the basis of all identified publications for that trial.
We had intended originally to interview the investi-
gators of trials where outcome reporting bias was sus-
pected for the review primary outcome and match the
interview to one from an investigator of a trial in the
same review where there was no suspicion of outcome
reporting bias. However, it became apparent early on
that matching would not be possible owing to the low
response rate. We therefore interviewed trialists from
within thesetwo groups without any attempt at match-
ing. To reduce potential problems with recall, we
restricted interviews to authors of trials published
since 2002; therefore, trials published since 2002
from Cochrane reviews that included at least one trial
where outcome reporting bias was suspected were eli-
gible for the current study.
Wealsodrewonasecondsource,PubMed,andran-
domly sampled trial investigators from the 14758 trial
reportsindexedonPubMedover the12 monthperiod
from August 2007 to July 2008. We used the advance
searchoptioninPubMedandsearchedforrandomised
controlled trials in human participants that were pub-
lished in English.
We aimed to conduct interviews with the trial chief
investigator, but also with the lead author where they
were different. Several strategies were used to identify
current contact details for these two groups of indivi-
duals. We began with the email address included on
the publication. These email addresses were often no
longer valid in cases where a considerable amount of
timehadelapsedbetweenapublicationandthisanaly-
sis.Inthissituation,wetriedtolocatemorerecentpub-
lications by the same author by searching electronic
databases. We then attempted to establish contact via
the website or directory of the author’s institution, by
contacting the journal in which the study was pub-
lished, or by searching for the author’s name using an
internet search engine such as Google. A further strat-
egy if these measures were unsuccessful was to contact
other authors the original author had recently pub-
lished with to request contact information.
Eligible trialists were contacted initially by an email
from one of the study team (RMDS) informing them
about the study and inviting them to take part in an
interview. The trial protocol was requested at this
point. One reminder was sent two weeks later to
those trial investigators who had not responded to the
first email. If no reply had been received within a
month of first contact, we assumed the trialist did not
want to take part and then consecutively invited coau-
thors to do so. Trial investigators who actively opted
out (declined to be interviewed) were asked to nomi-
nate a coauthor who could be approached. To maxi-
mise our sample, all those eligible and in agreement
were interviewed. Timing of the interview was there-
fore dependent on when the trialist or coauthor
responded to the email.
Sample size
Given the lack of similar studies, it was difficult to esti-
mate the number of trialists who would agree to be
interviewed. To maximise information on reasons for
discrepanciesinreportingofprimaryoutcomes,inves-
tigators from all trials included in a Cochrane review
that were suspected of outcome reporting bias for the
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view (n=85). In order to interview a similar number
of trial investigators from the other two groups—that
is, trials from the same Cochrane reviews that were
considered to show no outcome reporting bias and
the randomly selected cohort of PubMed trials—a
further 98 and 85 trialists, respectively, were
approached. The sample size was governed by prag-
matic considerations relating to the number of eligible
trials identified, the resources available, and the will-
ingness of trial investigators to participate.
Comparison of the trial protocol and publication(s)
Before interview, two researchers (RMDS and JJK)
independently assessed consistency of the trial proto-
colwithitsrelatedpublication(s)toidentifyanydiscre-
pancies in outcomes. For each trial we reviewed all
associated published articles. All trial reports were
written in English; conference abstracts and posters
were excluded.
Unreported outcomes were defined as those that
were prespecified in the trial protocol but were not
reported in any subsequent publications. For each
trial where selective outcome reporting was identified,
an “aide memoire” for the interview was produced
showing the outcomes prespecified in the protocol
and the outcomes published in the trial report.
Interview schedule
An interview schedule was devised to identify factors
influencing research reporting. The schedule had a
chronological structure that followed the sequence of
events for a trial: it started by establishing the research
question and discussing the writing of the study proto-
col; moved to trial conduct; and finally went through
the publication of the study findings. Where outcomes
were not reported as specified in the trial protocol, we
asked trialists to give an explanation and justification
for their decision making and an account of how deci-
sionsweremade.Trialinvestigatorswerealsoaskedto
provide the statistical significance of these unreported
outcomes if the data were collected and analysed.
The schedule comprised three broad areas of ques-
tioning:(a)specificquestionsrelatingtothepresenceof
selective outcome reporting (that is, selection of a sub-
set of the original recorded outcomes for inclusion in
the trial publication (see below)); (b) specific questions
relatingtowritingthemanuscriptandgettingthepaper
published;and(c)generalquestionsrelatingtopublica-
tionbias.Thiscurrentpaperaddressesthefirstofthese
areas; qualitative data obtained from the interviews
that explore trialists’ experiences more generally of
carrying out and reporting research will be reported
in a separate paper. Trial investigators had a copy of
the trial protocol and subsequent publication(s) with
thematthetimeoftheinterview,asdidtheinterviewer.
Specificquestionswereaskedrelatingtothepossibi-
lity of selective outcome reporting; that is, whether a
subset of the original recorded outcomes was selected
for inclusion in the trial publication:
 Were data for the unreported outcome collected?
If not, explore with trialist why not
 What was the trialist’s perception of the
importance of the outcome(s)?
 Why were data on the prespecified outcome(s)
not collected?
 What did the trialist consider were the benefits,
limitations, and difficulties associated with not
collecting data on the prespecified outcome(s)?
 If data on the unreported outcome were
collected, were they analysed?
If not, explore with trialist why outcome data
were not analysed
 What did the trialist consider were the benefits,
limitations, and difficulties associated with
analysing prespecified outcome(s) data?
 Why is reporting all prespecified outcomes
important?
 Why were the analysed outcome(s) not reported?
 What did the trialist consider were the benefits,
limitations, and difficulties associated with not
reporting the analysed outcome(s)?
 What was the statistical significance of the
unreported analysed outcome?
Explore with trialists the meaning of statistical
significance generally
Explore with trialists the importance or not of
the statistical significance of the non-reported
outcome
Explore how the statistical significance of an
outcome might influence reporting
Table 1 |Characteristics of trialists who responded to the invitation to participate in the study
and those who did not
All
(n=268)
Responded
(n=59)
Did not respond
(n=209) χ2 P value
Cohort
Randomly selected from PubMed 85 21 (25%) 64 (75%)
Identified in Cochrane reviews:
Suspected of outcome
reporting bias*
85 17 (20%) 68 (80%) 0.056 0.812
Not suspected of outcome
reporting bias*
98 21 (21%) 77 (79%)
Trial sample size
<100 122 28 (23%) 94 (77%) 0.627 0.731
100-999 128 26 (20%) 102 (80%)
>1000 18 5 (28%) 13 (72%)
Total 268 59 209
Funding
Non-commercial 105 33 (31%) 72 (69%) 10.064 0.018
Industry 116 21 (18%) 95 (82%)
Unfunded 1 0 (0%) 1 (100%)
Not stated 46 5 (11%) 41 (89%)
Total 268 59 209
Statistician involved
Statistician involved 17 7 (41%) 10 (59%) 5.012 0.082
Statistician involvement unclear 45 12 (27%) 33 (73%)
No information provided 206 40 (19%) 166 (81%)
Total 268 59 209
*In relation to review primary outcome.
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experience of qualitative research and of interviewing
clinicians (RMDS). Two trialists requested, and were
provided with, their interview transcript in order to
add to or clarify issues and to ensure validity of the
account produced; neither changed their accounts.
Initially, we had not planned to exclude trialists on
the grounds of first language. Three pilot interviews
were performed with trialists from non-English speak-
inginstitutionswhosefirstlanguagewasnot Englishto
assess the feasibility of carrying out interviews with
such individuals, with respect to information given
and interpretation. Email follow-up was then underta-
ken to verify the authors’ responses and our under-
standing of the information they gave. These
interviews are included in the analysis. However,
therewassomedifficultyelicitingdataandinformation
because of the language barriers, and follow-up ques-
tions were required by email. Given the resource
implications of follow-up, we decided that inclusion
should be limited to trialists working at institutions
where English is usually spoken.
Analysis
Each interview was tape recorded with the trialist’s
permission,transcribed,andanonymised.Allthetran-
scriptswereexaminedindetailbyoneoftheinvestiga-
tors (RMDS). At this stage interpretations were shared
with two of the other investigators—one a medical
sociologist with extensive qualitative research experi-
ence (AJ), the other a statistician with recognised out-
come reporting experience (PRW)—both of whom
read the transcripts independently. Data obtained
from the trial investigators in response to the explicit
questionsrelatingtothepresenceofoutcomereporting
bias were of particular interest.
Reasons provided by the trialists for not reporting
prespecifiedoutcomeswereclassifiedbytheinvestiga-
tors (AJ, PRW, and RMDS). Categories for outcome
reporting were preset and added to or modified as
newresponsesemerged.Throughdiscussiontheinves-
tigators reached a consensus regarding the categories
for classification of the reasons for discrepancies: (a)
the outcome was measured and analysed but not
reported; (b) the outcome was measured but not ana-
lysed; (c) the outcome was not measured; and (d) the
outcome was reported but not prespecified in the pro-
tocol.Aparticularreportingpracticewasdeemedtobe
associated with bias if the reason for non-reporting of
an analysis was related to the results obtained; for
example, if the result for the outcome was non-signifi-
cant.
ForsometrialsfromCochranereviewsidentifiedby
the ORBIT project, we already suspected outcome
reporting bias if trials did not report or partially
reported results for the review primary outcome on
the basis of all identified publications for that trial.
For this reason, estimates of the frequencies of various
discrepanciesinreporting
6arebasedonlyondatafrom
therandomlyselectedcohortidentifiedfromPubMed.
However, the reasons given by the trial investigators
for selective reporting are provided for all cohorts
together.
RESULTS
Response rate
Atotalof268trialswereidentifiedforinclusion;183of
these were from the cohort of trials covered in
Cochrane systematic reviews and 85 were randomly
selected from PubMed. One hundred and sixty one
of the 268 respective investigators acknowledged
receipt of our email, of whom 31 (19%) declined our
invitation. For those authors who did not respond to
emails, we were unable to ascertain whether this was
becauseofincorrectorinvalidcontactinformationand
hencenon-receiptofourinvitation.Wewereunableto
obtain contact details for chief investigators or lead
authorsfor19(7%)trials;however,weestablishedcon-
tact with coauthors for eight of these.
Thirtyonetrialists(includingsixcoauthors)declined
to be interviewed. The majority (17 trialists) gave no
reason for doing so. Those who did provide reasons
for declining cited personal circumstances (five trial-
ists), work commitments (four trialists), and difficulty
in recalling the trial (three trialists). One trialist did not
wish to be interviewed by telephone, preferring email
orwrittencontactonly.Onetrialistrequestedacopyof
the ORBIT protocol, and subsequently declined to be
interviewed.
Overall, 130 (81%) trialists initially agreed to be
interviewed (113 chief investigators or lead authors;
17 coauthors), but further attempts to establish contact
and request their trial protocols proved unsuccessful
for 30 of these. A further 35 trialists were unable to
provide a copy of their trial protocol and so were not
interviewed: 15 were unable to locate a copy, 13 were
unable to disclose details of their protocol because of
restrictions imposed by funding bodies (funded solely
byindustry),fivehadprotocolsthatwerenotwrittenin
English, and two trialists were unwilling to share their
protocolwithus,bothstipulatingthatitwasaconfiden-
tial document. Six further trialists agreed to be inter-
viewed and provided a copy of their protocol, but did
not respond to any further email contact.
All those eligible and in agreement were inter-
viewed. Overall 59 (37%) trialists, 38 identified from
the cohort of trials from Cochrane reviews and 21
from trials recently indexed in PubMed, were inter-
viewed (fig 1). Characteristics of the publication(s)
were compared between trialists agreeing (n=59) and
those not agreeing(n=209) tobe interviewed(table 1).
A higher proportion of trialists who did not agree to
interview were funded by industry. There was some
evidence that investigators for trials with reported
involvement of a statistician were more likely to
agree to be interviewed. There was no evidence of
any association between a trialist agreeing to be inter-
viewed and the sample size of the trial. Importantly,
therewasnoevidenceofanassociationbetweenagree-
mentrateandthelevelofsuspicionofoutcomereport-
ing bias, as indicated by the two groups of trials
identified from Cochrane reviews.
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Mostinterviews(48/59,81%)wereconductedwiththe
trial chief investigator, eight of whom were PhD stu-
dents. A further eight interviews were conducted with
the lead author and three with a coauthor. Additional
data were obtained at the time of the semistructured
interviews to provide a descriptive summary of the
sample. Characteristics of the interviewees and trials
are shown in table 2. Trialists were based in Australia,
Canada,Germany,theNetherlands,NewZealand,the
United Kingdom, and the United States.
The median publication year was 2005 (range 2002-
2008). In all but one case, interviews were performed
with one trial investigator from each trial; for one trial
we interviewed the chief investigator, lead author, and
statistician simultaneously at their request. Interviews
lasted on average 56 minutes (range 19-96 minutes).
Description of protocols
Forty three (73%) trialists sent their full study protocol
forreview.Thequalityoftheprotocolswashighlyvari-
able, but all lacked some key information such as a
clear definition of the primary outcome or a descrip-
tion of the statistical methods planned for the analysis.
For the remaining 16 (27%) trialists, no complete pro-
tocol was available. Instead, six trialists provided the
ethics committee application, two the funding applica-
tion, one a summary of the full protocol, and three
extracts from relevant chapters of doctoral theses. For
one trial the protocol sent was simply a letter with the
description of the trial that was sent to the funders. For
two trialists the full protocol was available but not in
English,so anEnglishsummarywasprovided.Forthe
remaining trialwe obtained an abridged version of the
protocol from the clinical trials.gov website.
In just under half of the protocols and substituted
documents (27/59, 46%), one primary outcome was
explicitly specified. In four (7%) protocols more than
one outcome was specified, and in 28 (47%) none was
specified. In three cases where a primaryoutcome was
not explicitly stated, we assumed that the outcome
usedinthesamplesizecalculationwastheprimaryout-
come; in two of these cases, this matched the stated
primary outcome in the publication. In the remaining
trial, the stated primary outcome in the report did not
match the outcome on which the protocol sample size
calculation was based. For three further trials where a
primaryoutcomewasnotexplicitlystated,weassumed
that the primary outcome related to the main aim as
stated in the research question in the protocol. Across
the 37 trials with explicit (31 trials) or implicit (6 trials)
primary outcomes, a total of 233 secondary outcomes
werespecifiedintheprotocols(medianoffive,range1-
17). For the remaining 22 protocols where we could
not deduce clearly which outcome was the primary
outcome, a total of 132 outcomes were specified in
the protocols (median of five, range 1-21). For the 59
protocols together,a total of 419 outcomeswere speci-
fied; the median number of all outcomes specified was
six (range 1-21). A statistical analysis plan was pro-
vided in 40 (68%) protocols.
Reasons for discrepancies in reporting of an individual
outcome
Inconsistencies of reporting were divided into those
where an outcome specified in the protocol was
omitted in the subsequent publication and those
where an outcome presented in the publication was
notprespecifiedintheprotocol.Alldiscrepanciesiden-
tified across all 59 trials are included here. These cate-
gories are mutually exclusive for a particular outcome.
Prespecified outcome measured and analysed by the time of
the primary publication but not reported
Sixteen trial investigators failed to report a total of 30
analysed outcomes. For the majority (15/16, 94%) of
the trials, this was judged to have led to biased under-
reporting (table 3). Although the decisions made by
trialists not to report outcomes potentially induced
bias, the information provided by trial investigators
confirmed that, in all but one case (trialist 30), not
reporting an outcome was unintentional. The most
commonreasonsgivenbythetrialistsfornotreporting
outcomeswererelatedtoalackofunderstandingabout
the importance of reporting “negative” results (trialists
12,18,22,29,44,49,and50),thedatabeingperceived
tobeuninteresting(trialists09,18,and36),therebeing
toofeweventsworthreporting(trialists12,39,and41),
Invited for interview (n=268):
  Cochrane reviews (n=183)
  PubMed sample (n=85)
Trialist agreed to interview (n=130):
  Cochrane reviews (n=90)
  PubMed sample (n=40)
Excluded (n=138): 
  Unable to trace trialist (n=11) 
     Cochrane reviews (n=10) 
     PubMed sample (n=1) 
  Trialists declined (n=31) 
     Cochrane reviews (n=19) 
     PubMed sample (n=12) 
  Trialist did not respond to email (n=96) 
     Cochrane reviews (n=64) 
     PubMed sample (n=32)
Trialists interviewed (n=59):
  Cochrane reviews (n=38*)
  PubMed sample (n=21)
Excluded (n=71): 
  Further contact with trialists to obtain trial
    protocol proved unsuccessful (n=30) 
      Cochrane reviews (n=17) 
      PubMed sample (n=13) 
  Trialist unable to send protocol (n=35) 
    Cochrane reviews (n=31) 
    PubMed sample (n=4) 
  Trial protocol received but further contact
    with trialists proved unsuccessful (n=6) 
      Cochrane reviews (n=4) 
      PubMed sample (n=2)
Trialists eligible for interview. *Includes 17 associated with
trials suspected of outcome reporting bias, 21 responsible for
trials with no outcome bias suspected
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imposed by the journal (trialists 32, 34, and 56).
Therewasdeliberatemisrepresentationoftheresults
in one trial, in which a statistically significant increase
inharmintheinterventiongroupwassuppressed.The
investigator for this trial (trialist 30) describedthe diffi-
cultiespresentedbysuch a result,includingthe discus-
sions the team had with each other and the wider
clinical and research community, and the potential
impact reporting the data would have had on service
providers.
Prespecified outcome measured by the time of the primary
publication but not analysed or reported
Data on 26 outcomes over 17 trials were collected but
subsequently not analysed. Most reasons given by the
trial investigators were not considered to indicate bias
(table 4). However, in four trials, the direction of the
main findings had influenced the investigators’ deci-
sion not to analyse all the data collected. In three of
these trials, results for the primary outcome were
non-significant and analyses of some of the secondary
outcomes were therefore considered of no value (trial-
ists05,39,and44).Theremainingtrialist,afterfinding
anincreaseinharmfortheprimaryoutcome,chosenot
to analyse a secondary outcome (trialist 59).
Other reasonsgiven by the trialists for not analysing
collected outcome data included: inadequacies in data
collectionresultinginmissingdata(trialists20and23);
longtermdatanotbeingavailablebythetimeprimary
outcome data were published (trialists 08, 23, and 43);
delay in obtaining the data (trialists 40, 42, and 53);
practical difficulties leading to uncertainty regarding
the validity of the results (trialist 55); cuts in govern-
ment funding meaningfull analysiswas not financially
viable (trialist 15); a large volume of data presented in
primary publication (trialist 45); and practical difficul-
ties associated with the organisation of the trial (trialist
27). One trialist (trialist 41) had problems associated
with not meeting the prespecified sample size, and an
additionaltrialinvestigator(trialist31)failedtoanalyse
one outcome because the trial had a lower than
expected recruitment rate (the prespecified sample
size was 112, but only 54 participants were recruited),
so the researchers decided to analyse fewer outcomes.
Prespecified outcome not measured
Thirteen prespecified outcomes across five trials were
not measured over the course of the trial. Reasons
givenbythetrialinvestigatorsrelatedtodatacollection
being too expensive or complicated, as well as there
being insufficient time and resources to collect less
important secondary outcomes.
Outcome reported but not prespecified in the protocol
An additional 11 outcomes were analysed and
reported without being prespecified in the five respec-
tive trial protocols. The reasons that the trialists gave
were associated with poor research practice and were
attributed to shortfalls in the writing of the protocol.
For example, one trialist acknowledged that only at
the point of compiling the case report forms did they
consider collecting data on the outcome, a decision
thatwasmostlyinfluencedbythefactthattheoutcome
was routinely measured by clinicians.
Frequency of outcome reporting bias
Estimatesofthefrequenciesofvariousdiscrepanciesin
reporting are based only on data from the randomly
selectedcohortidentifiedfromPubMed,becausetrials
identifiedfrom the ORBIT project were not randomly
selected.Inthe21PubMedtrials,theprimaryoutcome
statedintheprotocolwasthesameasinthepublication
in 18 (86%) cases. Of these 18 studies, three were
fundedsolelybyindustry,ninewerenotcommercially
funded, and six received funding from both industry
Table 2 |Characteristics of trial investigators and trials included in the study
Trialists from Cochrane review cohort
Trialists from PubMed cohort
(n=21)
Suspected of outcome
reporting bias (n=17)
Not suspected of outcome
reporting bias (n=21)
Previous research experience
Extensive 10 (59%) 7 (33%) 15 (71%)
Coauthor had experience 7 (41%) 10 (48%) 4 (19%)
No experience in research team 0 4 (19%) 2 (9%)
Sample size
<100 6 (35%) 11 (52%) 11 (52%)
100-999 8 (47%) 9 (43%) 9 (43%)
>1000 3 (18%) 1 (5%) 1 (5%)
Funding
Non-commercial 10 (59%) 15 (71%) 11 (52%)
Industry 7 (41%) 5 (24%) 10 (48%)
Unfunded 0 1 (5%) 0
Statistician involved
Throughout trial 9 (53%) 8 (38%) 13 (62%)
Consulted 1 (6%) 5 (24%) 6 (29%)
No statistician involved 7 (41%) 8 (38%) 2 (10%)
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Trialist Explanation from trialist Category
09 “It was just uninteresting and we thought it confusing so we left it out. It didn’t change, so it was a result that we . . . you know, kind of not particularly
informative let’s say, and was to us distracting and uninteresting.”
Bias
12 “There was no mortality. No mortality at all”
“I had the idea that they would change with the intervention, but they didn’t change and that is why they were never reported. It was the negative result,
which is also a result, but we never report on it. Normally I would have published these, I also publish negative data, but we thought that these data would
explain why the intervention should work and that these data did not show, so that’s why but normally I would certainly publish negative results.”
Bias
18 “We didn’t bother to report it, because it wasn’t really relevant to the question we were asking. That’s a safety issue thing; there was nothing in it so we
didn’t bother to report it. It was to keep ethics committee happy. It is not as if we are using a new drug here, it is actually an established one, just an
unusual combination, so if we are using new things we report all that sort of stuff, so it’s not that experimental. We didn’t bother to report it, because it
wasn’t really relevant to the question we were asking.”
“They’re kind of standard things in the bone world and they never show anything unless you have 5000 people, I’m exaggerating, 500 people in each group.
In the end there was nothing really in it, I mean there were no differences, it was a short duration study, very small numbers, so actually the chances of
finding anything was very small. Even if we found something it was likely to be confounder, there was a statistical chance. I think the protocol was adapted
from a kind of a standard one we used for lots of drug trials and some of those bits could have been left out actually.”
Bias
22 “The whole study showed that there was nothing in the [intervention]. So the whole study was actually a negative result, so I don’t think the fact that there
was no effect prevented me from putting it into the paper. It was either possibly an oversight or possibly something I thought, ‘well this isn’t relevant.’”
Bias
29 “When I take a look at the data I see what best advances the story, and if you include toomuch data the reader doesn’t getthe actual important message, so
sometimes you get data that is either not significant or doesn’t show anything, and so you, we, just didn’t include that. The fact that something didn’t
change doesn’t help to explain the results of the paper.”
Bias
30 “When we looked at that data, it actually showed an increase in harm amongst those who got the active treatment, and we ditched it because we weren’t
expecting it and we were concerned that the presentation of these data would have an impact on people’s understanding of the study findings. It wasn’ta
large increase but it was an increase. I did present the findings on harm at two scientific meetings, with lots of caveats, and we discussed could there be
something harmful about this intervention, but the overwhelming feedback that we got from people was that there was very unlikely to be anything harmful
about this intervention, and it was on that basis that we didn’t present those findings. The feedback from people was, look, we don’t, there doesn’ta p p e a r
to be a kind of framework or a mechanism for understanding this association and therefore you know people didn’t have faith that this wasa valid finding, a
valid association, essentially it might be a chance finding. I was kind of keen to present it, but as a group we took the decision not to put it in the paper. The
argument was, look, this intervention appears to help people, but if the paper says it may increase harm, that will, it will, be understood differently by, you
know, service providers. So we buried it. I think if I was a member of the public I would be saying ‘what you are promoting this intervention you thought it
might harm people—why aren’t you telling people that?’”
Bias
32 “If we had a found a significant difference in the treatment group we would have reported that, and it certainly would have been something we probably
would have been waving the flag about. To be honest, it would have come down to a word limit and we really just cannot afford to report those things, even
a sentence used, and often you have a sentence about this, and a sentence about that, and so it doesn’t allow you to discuss the more important findings
that were positive or were negative as some of our research tends to be, because I guess it’s a priority of relevance”
Bias
34 “No I think probably, it’s possible, I am looking on the final one, but probably was each time, reduced and reduced from the start to submitting to the
journal. It is very limited on numbers, probably we start to . . . it didn’t get accepted so we kind of cut and cut, I believe this is what happened.” (the
manuscript went to four journals)
Bias
36 “It’s as dull as ditchwater, it doesn’t really say anything because the outcome wasn’t different, so of course [trial treatment] is going to be more expensive
and no more effective so of course it’s not going to have a health economic benefit. Because you have got two treatments that don’t really differ. I just think,
we have got to find a different way of . . . so for example I said well can’t we say something about the costs within the groups of those who relapsed and
those who didn’t, just so that people get a ball park, but it’s written and he [coauthor—health economist] wants to put it in as it is, and I don’th a v ea
problem with that, it’s rather a sense of I am not sure what it tells anybody.”
Bias
39 “We analysed it and there was two patients who had the outcome, you know one in each arm, so we decided the numbers were so small that we didn’tt h i n k
that adding another row to the table to describe two patients added anything.”
Bias
41 “Patients in this particular trial turned out to use very low amounts of drugs. So, there was nothing essentially to compare. The use of other drugs was nota n
important issue in this population. There was nothing to report. There was no reportable data, no interesting story in the secondary outcome data, and our
intention was always to focus on the opiate use not on the other drugs. I did look, we do have data on other drug use, we have collected data as we
promised, but essentially there is nothing to report in this data. Patients do not use other drugs heavily. We will present again, I have all the intentions, the
data is available for analysis and for presentation if one of my students decide to do some work with this and help me out with this, absolutely it will get
published, but I have to pick and chose what I am actually working on.”
Bias
44 “We probably looked at it but again it doesn’t happen by magic. So, I can’t imagine that there would be a difference. Why we didn’t? My guess is that we
didn’t look at it because that is something that has to be prospectively collected, and so I would assume that we collected it and there was just absolutely
no difference, but I don’t recall. I am pretty sure there would not be differences, it would be related to temperature, but what the results were I don’t
remember at this point.”
Bias
49 “Yes because what happened is, I am left with a study where everything is [non-significant], even though we walked in believing that we would see a
difference, and even though we had some preliminary information, you know anecdotal, that there should be a difference, there was no difference. So, it
really turned out to be a very negative study. So we did collect that information, and again it’s a non-result, but there are only so many negative results you
can put into a paper.”
Bias
50 “It didn’t add anything else to the data, it changed but it wasn’t anything that was remarkable, it wasn’t a significant change. If it had been something that
either added additional strength to the data, or if it was conflicted, if it turned out it went totally against our data, and was counteractive to what we were
saying, yes we would have reported.”
Bias
54 “Yes, we have those data on file, and I am sorry to say that we are writing-up so many papers sometimes we do not know what’s in the other papers. It has
been analysed, I know, because what I know right now is that all the measurements which would be performed in this study as well as in two other studies
were done, very simply because the outcome is very difficult to measure, well it’s very simple to measure, to get the antibodies is very difficult, and we got it
from an organisation that gave us just enough to do the measurements. I know the results, saying from what I have in my head the outcome is going up, we
have high levels of it, but I am not sure whether it was a significant increase or whether it was significant compared to the control group or the other group
as mentioned in the study.”
Delay in
writing up of
secondary
outcomes
beyond
primary
publication
56 “I actually disagree that this outcome is important, but that was probably a more pragmatic aspect of making sure that our protocol was funded, because I
think some reviewers might have said, ‘wow you are not measuring this outcome!’ That said, there is a vast amount of literature showing that it’so f
completely no relevance but it was a practical decision to make sure we got money. Once we conducted the study and reflected on our results more we just
didn’t think it had that much validity in telling us very much about the condition. So for the sake of brevity we didn’t report that. I didn’t expect there would
be much of a difference, and our results show that there wasn’t much of a difference.”
Bias
RESEARCH
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Trialist Explanation from trialist Category
05 “I think, you know, the issue withcost is it would have been relatively easy to get hospital charges, but actual costs
are more complicated analysis, and given that there was no difference between the groups we didn’t go onto that.”
Secondary data not analysed because no difference in
primary outcome
08 “Part of the problem is, as our economists keep on telling us, we have been collecting economic data, but we
haven’t had enough of them. So for instance, for someone going into treatment, you know, we still don’t have a lot
of participants who are receiving treatment. So, one thing that we now have is older participant rates, so the
economists are just starting to work on that, saying: ‘OK, now that we have older rates, we can project out what
potential benefits in terms of like earnings over a life course, we might expect.’”
Long term outcome data not obtained by the time
primary outcome data published
15 “Unfortunately, the yearwewerefundedthe fundersleviedlargeacross the board cutstoall approvedprojects. Our
recruitment also took longer than expected. As a result, we had neither the time nor the resources to analyse for
effects on the several less important secondary or exploratory outcomes we mentioned in our initial proposal.”
Insufficient time, resources, or both to analyse less
important outcomes
20 “The problem was that they weren’t completed as well as all the other measures, it was only just over two thirds of
people who consistently completed their diary, so it would have reduced our numbers considerably.”
Not analysed because of the amount of missing data
23 “It was missing, a lot of people were missing data, and because we were looking at pre- and post- if they were
missing at either point then we had to throw out that person, so we just didn’t have enough, and then across three
different conditions, so if you have only six or seven people with data in each condition it really wasn’tw o r t h
looking at.”
“Oh I knowwhatitwas;I doknow what itwas. WellI know why itwouldn’t havebeen inthe dissertation. I endedup
getting pregnant, and so I actually defended the dissertation early, so I defended the dissertation before all of the
six months data were collected, even though I said I would do all of it, and I did, but I wanted to get the defence
done beforeI wentonmaternityleave,so they allowedmetodefend just based onthe pre-postdata, and wedidn’t
collect the health services data until six months, so I didn’t have those data at the time that I defended. Now I did
include the follow-up data in this published article but I probably yes, I didn’t go back and probably didn’t even
code and clean all the data we collected on health services.”
Not analysed because of the amount of missing data
Long term outcome data not obtained by the time
primary outcome data published
27 “Samples were taken and one could argue that this is unethical actually because those samples were taken, and
stored, and frozen, and the results of analysis have never been published because the analysis was never done.
Speaking as someone who is interested in trial ethics, that is probably unethical to take samples and not analyse
them. Here is the answer to that question then, it’s really simple issue, which is the reality of doing a trial. This was
an utter nightmare. For the analysis we did all the preparation abroad, it was an utter nightmare. I wouldn’ts a yI
still wake up screaming. For a small aspect of a trial, you know, some of the more interesting outcomes and
laboratory based things to support whatever the hypothesis is, it grew to assume gargantuan proportions because
there was no electricity, it was 40 degrees, there were bugs crawling around everywhere, and this turned into a
nightmare. Getting it back to . . . there were no facilities to do these in the country and getting it back to us was a
nightmare. And, the reason for the reporting differences for this biochemical stuff is actually I suspect not to do
with bias but to do with pragmatics.”
Not analysed because of practical difficulties
31 “The main reason was limited power, so we had fewer variables up front, because of small sample size. Most of it
was driven by the small sample size, you know when you have 54 participants and you are trying to look at
outcomes, so we made decisions about what seemed to be the most important variable. I think I tend to be
conservative and part of this is just the sample was so small. I have tried to be very focussed in the papers and
there is lots of data that is lying dormant essentially because of that.”
Limited analysis undertaken owing to poor recruitment
39 “No, we haven’t analysed it yet, you know we saw no effect on [primary outcome], which means that the drug is not
evergoingtoget, wellnotinthe foreseeable future, goingtogetonthe market.SoIthinkit’s less important, people
aren’t going to have access to it, it’s less important to share, to make that data public given the low likelihood that
it’s going to show anything. It’s not going to have any immediate clinical implications for anybody.”
Secondary data not analysed because no difference in
primary outcome
40 “Well, we will be doing it, so what happens is you send someone down to a laboratory, they do the various
procedures and then you have to have someone who scores the protocol, which requires various software and
code writing, and then someone to spend the time to actually analyse the data. And, it just, it takes a while and so
our primary interest was getting out the information, these other measures were more secondary outcome
measures. It gets into issues around priorities, staff leaving, new staff having to be trained, it has just taken us a
while to get thisstuff analysedand asI saidit’s,ithas beenanalysedand weare hopingto write the manuscript for
this, this fall.”
Delay in obtaining the data
41 “The cost effectiveness was really not conducted in this study. I am not an expert on cost effectiveness, there is a
different team that works with us on cost effectiveness analysis, and this is their own survey now. And also the
size, the effect sizes to be expected for the cost effectiveness analysis are much smaller and therefore the sample
size did not really afford this type of analysis.”
“Thereis also a limit ofwhatnumber of statistical analyses you can actually reliably dowitha small sample size, so
considering the sample size of this particular study, we decided to report only on the really main primary selected
outcomes and not run many analysis, because we understand that they lose the power, and they lose the power of
the conclusion.”
Not analysed because of poor recruitment
42 “Well that, itturns outthatourfunders [industry] kind ofwent through some internal reorganisation, and as a result
there are delays in the analyses of this outcome, and so we are still waiting to receive the final data from that, to
publishit. We havegotpartial data completed on thatpart ofthe project but not complete. The data, it’sr e a l l yh e l d
byus. The funders havethe samples,theyjusthavethatone setofsamples, and theysendusthe dataand weown
the data and do the analysis, they just did the assay. We are interpreting it and analysing it and everything.”
Delay in obtaining the data
43 “The economic evaluation, it’s in processes. Well, we were supposed to have it analysed by the end of the month, I
can’t give you any preliminary. We know about the utilisation already but I don’t know about the related costs. Our
goal is to have it actually submitted this year.”
Long term outcome data not obtained by the time
primary outcome data published
44 “So it was a negative trial, it was not a failed trial, we have statistical power, but it was negative basically, we
showed that in the context of our environment the intervention did not increase the primary outcome so basically
the outcomes were identical in the two groups. Given this there was absolutely no reason to expect the difference
in anything we would measure in the blood. So, we had collected all that, it was sitting in the refrigerator, in the
freezer, so we didn’t do the analysis because it was completely obvious that it would be negative.”
Samplesnot analysed because no difference in primary
outcome
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primary outcomes specified in the protocol and those
listed in the trial report were found in three trials. In
onetrial,theprimaryoutcomeasstatedintheprotocol
was downgraded to a secondary outcome in the pub-
lication, and a non-primary outcome with statistically
significantresults(P<0.05)waschangedtotheprimary
outcome. One trial omitted reporting three prespeci-
fiedprimaryoutcomesandincludedinthepublication
a new primary outcome (P<0.05) not stated in the pro-
tocol. Both trials were not commercially funded. The
remainingtrialmeasuredbutdidnotanalyseoneofthe
eight prespecified primary outcomes; funding here
camefrombothindustryandnon-commercialsources.
Atotalof159outcomeswereprespecifiedacrossthe
21 trials. Across the 21 trials, 26 (16%) of the 159 out-
comeswerenot reported,ofwhichfour wereprespeci-
fied primary outcomes in two trials. There was at least
one unreported efficacy or harm outcome in 14 trials
(67%),ofwhichseven(64%)werenotcommercialtrials
and seven (70%) had joint industry and non-commer-
cial funding. Unreported secondary outcomes were
eithernotmeasured(twotrials),measuredbutnotana-
lysed (12 trials), or measured and analysed but not
reported (eight trials). Four trials reported five out-
comes that were not prespecified.
Giventhe statedreasonsfordiscrepancies,six (29%)
of the cohort of 21 trials were found to have displayed
outcome reporting bias—that is, non-reporting of an
outcome was related to the results obtained in the ana-
lysis (trialists 39, 41, 44, 49, 50, and 56).
DISCUSSION
Researchers have a moral responsibility to report trial
findings completely and transparently.
16 Failure to
communicate trial findings to the clinical and research
communityisanexampleofseriousmisconduct.
17Pre-
vious research has shown that non-publication of
whole studies or selected results is common, but there
has been little previous research into the awareness
among researchers of their responsibilities to publish
fully their research findings or of the possible harm
associated with selective publication.
Principal findings
When comparing the trial protocol with the subse-
quent publication, we carefully distinguished the
cases where an outcome was measured and analysed
but not reported, measured but not analysed or
reported, and not measured. There are two key mes-
sages from our work. Firstly, most unreported out-
comes were not reported because of a lack of a
significant difference between the trial treatments,
thus leading to an overoptimistic bias in the published
literature as a whole. However, we believe that non-
reporting mainly reflected a poor understanding of
how any individual trial forms part of the overall evi-
dence base, rather than intentional deception. Sec-
ondly, from the reasons given for outcomes being
either measured but not analysed or not measured,
therewasagenerallackofclarityabouttheimportance
and feasibility of data collection for the outcomes cho-
sen at the time of protocol development.
We identified one study, however, in which the tri-
alists intentionally chose to withhold data on a statisti-
cally significant increase in harm associated with the
trial intervention. This type of “distorted reporting”
in relation to adverse events has been previously
described.
18 The reported findings from the trial were
published in a prestigious journal, and since publica-
tion the paper has been cited by others on a number of
Trialist Explanation from trialist Category
45 “That outcome is a paper still in the making. That data was kept completely aside, you know, as you can see the
paper that we are talking about has got so much in it and we did hum and ah whether we were going to break it
down or present it separately, or any of that sort of stuff, but when we did come down to it, this outcome was just
going to be too much again for that paper and so we chose to leave it and it’s still a paper in the making, it’ss t i l l
data which is sitting there and hopefully will be a standalone paper in itself. I haven’t got round to analysing it, I
have gone out of a PhD and jumped straight into something else, I have still got data and all sorts of stuff that I
haven’t even have time to enter. I get the impression from talking to others as well that it’sa l w a y sc o m m o nw h e n
you collect a lot of data to have one or two variables that never make it to the cutting board. So this outcome is not
in my thesis. I would like to think that it will reach publication one day. I think at the moment I am very, I am very
rushed with all the new things that I have got on my plate, but there is a number of variables that I breeze back on
and think to myself ‘oh I will do something about that one day, I will do something about that one day.’ So yes I
would like to think that it wasn’t, it wasn’t a wasted time in collecting it.”
Outcome not analysed because volume of data
presented in primary publication
53 “Right, we did that and just because it takes absolutely for ever to score it, and although I am a trained scorer as a
primary investigatorI can’tdothe scoring, soIhad tosendone ofmyteammemberstogettrained and itjust takes,
it is taking forever to get through them all, so it’s still in the pipeline. I would have had to postpone the writing of
the primary outcome paper if I had to wait for this data. Yes, we have almost just about done now and so in a
separate publication we will report that.”
Delay in obtaining the data
55 “Doing the measurements is really hard and I wasn’t sort of specifically trained to do them. I mean the clinicians
told me how to do them, but it can be quite difficult to do. Which is a shame because that is a nice sort of, a nice
measurement to have. We did it the whole way through but kind of knowing that it was pointless. I think, because
we ended up doing it for the trial participants rather than for us, because they expected it to be done. So we just
did it and noted it down but never analysed it, because we didn’t believe in it, even if it had shown something
brilliant, we wouldn’t have thought it was true.”
Not analysed because of practical difficulties and
uncertainty about validity of data
59 “I thinkithad justfallen offour radar screenand wewerefocused ontheprimaryoutcome, because the story would
havebeen ‘you reducethe outcome, and a higher proportionofpeopleremainindependent.’ Infact,wesort ofthen
began telling another story. It didn’t seem important once we had already frightened ourselves by showing that we
caused harm and I suppose the story could have been ‘you cause harm and you cause more people to have to go
into care.’ I think it just fell off the radar screen because we then began to worry about why, why this didn’t work.”
Not analysed because harmful effect of intervention on
primary outcome
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make these unreported results publicly available.
We identified an apparent over reliance on the arbi-
trary but widely used cut off of 0.05 to distinguish
between significant and non-significant results. In
many cases trialists described subdividing P values
into “significant” and “non-significant,” and deciding
to not report “non-significant” results. Yet statistically
significant results may not always be clinically mean-
ingful. Likewise an observed difference between treat-
ment groups might be clinically important, yet fail to
reach statistical significance. Whether or not a finding
is reported should not depend on its P value.
Comparison with other studies
Our work provides richer information on trialists’
decision making regarding selective outcome report-
ing than previous work has been able to capture. Pre-
vious questionnaire surveys asked trialists about any
unpublished outcomes, whether those showed signifi-
cantdifferences,andwhythoseoutcomeshadnotbeen
published.
4815 Our work supports their findings and
providesamoredetailedunderstandingofwhytrialists
donotreportoutcomes.Previousstudiesdidnotestab-
lish whether or not trialists intentionally chose to mis-
lead by not reporting non-significant outcomes. Our
study suggests deliberate misrepresentation of the
results may be rare, although we cannot rule out the
possibility that trialists may have framed their
responses to our interview questions to hide inten-
tional under-reporting of outcomes.
An ongoing Cochrane review has identified studies
that compare trial protocols with subsequent publica-
tions (K Dwan, personal communication, 2010). The
effect of journal type was examined in one study but
was not found to be associated with selective outcome
reporting.
12 The effect of funding source on outcome
reportingbias seemsto be heterogeneous, with studies
showing that commercially funded trials are more
(D Ghersi, personal communication, 2010), less,
19 or
equally
20likelytodisplayinconsistenciesinthereport-
ing of primary outcomes compared with studies that
were not commercially funded. One study reported
no effect of funding source on whether outcomes
were completely reported,afteradjustingforstatistical
significance (E von Elm, personal communication,
2010), whereas another found that commercially
funded trials were more likely to completely report
outcomes (D Ghersi, personal communication, 2010).
For the 85 studiessuspected of outcome reporting bias
and the 98 studies assumed to be free of outcome
reporting bias in this project, there was little difference
betweenthegroupsintermsofsamplesizeortheinvol-
vement of a statistician. However, there was some evi-
dence that trials suspected of outcome reporting bias
were more likely to not state their source of funding.
The implications of our low response rate among trial-
ists involved in commercial trials is not clear. It is pos-
sible that our results for the prevalence of outcome
reporting bias are conservative, if those declining to
be interviewed did so to avoid exposure of such bias
with their studies.
Recent work has shown the harmful effect of selec-
tive outcome reporting on the findings of systematic
reviews
3 and also the lack of awareness among people
who conduct systematic reviews of this potential pro-
blem. Two recent initiatives are relevant here: firstly,
the inclusion of selective outcome reporting as a key
component of the new Cochrane risk of bias tool,
21
which all review authors should be using in future to
assess the trials included in a Cochrane review; and
secondly, the recommendation to consider this issue
when reporting a systematic review.
21 We hope these
developments will lead to greater recognition by
reviewersandusersofsystematicreviewsofthepoten-
tial impact of reporting bias on review conclusions.
Strengths and limitations of the study
Thestrengthofourstudyrestsinitsuseofinterviewsto
provide valuable insight into the decision making pro-
cess from the planning to the publication stage of clin-
ical trials. Our study adds to the growing body of
empiricalevidence onresearchbehaviour.
22 Outcome
reportingbiasandpublicationbiasmorebroadlycould
be viewed as forms of “fabrication,” according to the
definition given by the US Office of Research Integ-
rity. Our study leads us to agree with Martinson et al
that “mundane ‘regular’ misbehaviours present
greater threats to the scientific enterprise than those
caused by high profile misconduct cases such as
fraud.”
23 Outcome reporting bias and publication
bias more broadly were not explicitly mentioned in
Martinson et al’s survey, however, suggesting that the
scientistsfromwhomtheauthorsdrewthespecificmis-
behaviours to be surveyed were unaware of the harm-
ful effects of selective reporting.
It is important to acknowledge that the results pre-
sented come only from those trialists who agreed to be
interviewed, and thus we urge caution in the inter-
pretation of our study findings given the low response
rate (trialists who declined our invitation or could not
sendtheirtrialprotocolwerenotinterviewed).Thereis
limited evidence relating to the factors associated with
selective outcome reportingand even less with respect
to outcome reporting bias directly, making an assess-
ment of response bias in this current study difficult.
It is possible that different methods—such as postal
questionnaires—might have resulted in a higher pro-
portion of trialists agreeing to be interviewed. How-
ever, structured telephone interviews were
considered the most appropriate form of data collec-
tion when taking into account the aims of our study.
The style of the interview allowed similar topics to be
covered with each of the trialists, while still allowing
the trialists to have flexibility in their answers. It
allowed the prespecified topics to be discussed and
explored in detail, as well as new areas or ideas to be
uncovered. In addition, such interviews allowed the
interviewer to check that they had understood the
respondent’s meaning, instead of relying on their
own assumptions.
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size. All trialists eligible for interview were invited
(n=268),ofwhom59(22%)finallyagreed.Completion
of interviews was governed by pragmatic reasons (the
number of trialists who ultimately agreed), rather than
when there was no extra data gained from the latest
interview (data saturation).
Conclusions and policy implications
We are the first group to conduct interviews targeting
instances of outcome reporting bias and protocol
changes. Our findings add important new insights,
pointing to a lack of awareness and understanding of
theproblemgenerally.Trialistsseemedunawareofthe
implications for the evidence base of not reporting all
outcomesandprotocolchanges.Agenerallackofcon-
sensus regarding the choice of outcomes in particular
clinical settings was evident and affected trial design,
conduct, analysis, and reporting.
It has been suggested that comparing publications
with the original protocol constitutes the most reliable
means of evaluating the conduct and reporting of
research,
24 and the Cochrane Collaboration has
recommended such comparison to detect if complete
or incomplete reporting is indicated.
21 It is widely
believed that the introduction of trial registration
would remove the practice of retrospective changes
to outcomes, but a recent study has shown that there
arefrequentdiscrepanciesbetweenoutcomesincluded
on trial registers and those reported in subsequent
publications.
12 We have found that some differences
between the protocol and the publication are a result
of outcome reporting bias, but also that some changes
are made during the course of the trial as a result of
poor outcome choice at the protocol development
stage. Such differences do not lead to bias. Our work
suggests that for the assessment of reporting bias, reli-
ance on the protocol alone without contacting trial
authors will often be inadequate.
Our findings emphasise the need to improve trial
design and reporting. The recent update of the CON-
SORT reporting guideline
25 includes an explicit
request that authors report any changes to trial out-
comes after the trial commenced and provide reasons
for such changes. Readers can then judge the potential
forbias.Unfortunately,inourstudynoneofthereports
in which trial outcomes were not measured, or were
measured but not analysed, acknowledged that proto-
col modifications had been made.
Our finding of a lack of understanding of the impor-
tance of reporting outcomes in various clinical areas
lends further support to the development of core out-
come sets.
26-28 International efforts to develop consen-
sus on a minimum set of outcomes that should be
measured and reported in later phase trials in a parti-
cularclinicalareawouldleadtoanimprovedevidence
base for healthcare.
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